Taken together, this suggests that BDP1 is behaving similarly to an already established biomarker of serous ovarian cancer, NCOR2, in clinical samples treated with chemotherapies platin and taxane. The gene discussed is BDP1; the disease is ovarian serous adenocarcinoma.